WALD - Waldencast Acquisition Corp

WALD - Waldencast Acquisition Corp

https://www.waldencast.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Waldencast Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Waldencast ( NASDAQ:WALD )

Benzinga • 4 weeks ago • score: 0.12

Waldencast plc WALD will release earnings results for the second quarter after the closing bell on Monday, Aug. 18. Analysts expect the White Plains, New York-based company to report a quarterly loss at 5 cents per share.

Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand

GlobeNewswire • 1 month, 3 weeks ago • score: 0.24

Acquisition strengthens Obagi Medical's product portfolio with proven, scientifically backed, injectable portfolio ...

Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand - Waldencast ( NASDAQ:WALD )

Benzinga • 1 month, 3 weeks ago • score: 0.38

Acquisition strengthens Obagi Medical's product portfolio with proven, scientifically backed, injectable portfolio New products position Obagi Medical at the forefront of health, beauty and aesthetics convergence

Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Altimmune ( NASDAQ:ALT ) , Bit Digital ( NASDAQ:BTBT )

Benzinga • 2 months, 2 weeks ago • score: -0.55

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday. Shares of Altimmune, Inc. ALT fell sharply in today's pre-market trading after the company announced topline results from the IMPACT Phase 2b trial of Pemvidutide in the treatment of MASH.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-09 (Snapshot)

Waldencast Acquisition Corp. The company is headquartered in White Plains, New York.

52W High

$4.40

52W Low

$1.48

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.54

Valuation

Rich

As of 2024-12-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

45.05

EV/EBITDA (<8 favorable)

13.49

EV/Revenue (<3 favorable)

1.41

P/S (TTM) (<3 favorable)

0.80

P/B (<3 favorable)

0.33

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

57.01%

Institutions (25–75% balanced)

30.24%

Shares Outstanding

112,645,000

Float

32,851,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2024-12-31 (Overview)

Revenue (TTM)

273,868,000

Gross Profit (TTM)

191,744,000

EPS (TTM)

-0.39

Profit Margin (>10% good)

-0.16%

Operating Margin (TTM) (higher better)

-0.18%

ROE (TTM) (>15% strong)

-0.06%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.31

Momentum

Bearish momentum

Value

-0.1246

Previous

-0.1548

Trend

Rising

Signal Cross

No cross

As of

Sep. 05, 2025